Type 2 Diabetes Mellitus Clinical Trial
Official title:
Mind-motor Exercise in Older Adults With Type 2 Diabetes and Self-reported Cognitive Complaints
The purpose of this study is to determine if a 6 month mind-motor intervention will help to improve overall brain health in adults over the age of 55 with type 2 diabetes and a self-reported complaint about memory or thinking skills. It is hypothesized that the intervention group will show improvements in their overall brain health after 6 months of mind-motor training compared to the control group.
Dementia has been identified as a global health concern because of the increase in incidence
globally. Regardless of whether individuals with self-reported cognitive complaints (CCs)
have objective impairment, they are at increased risk for cognitive decline, and they are
comparable to those with early mild cognitive impairment (MCI) for brain atrophy and
increased risk of progression towards Alzheimer's disease (AD). People who express being
worried about their memory or cognition show a further increased risk of cognitive decline.
If prevention programs could delay the onset of dementia even in part of the at-risk
population, this could decrease disease prevalence significantly. The risk of cognitive
impairment or dementia is increased in type 2 diabetes (T2D) and T2D accelerates the
progression from MCI to dementia.
The proposed mind-motor intervention for the prevention of cognitive decline in T2D is
called square stepping exercise (SSE). The SSE program was developed by Shigematsu and Okura
(2005) and can be best described as a visuospatial working memory task with a stepping
response. There are more than 200 patterns developed for this program that progress from
simple to advanced stepping patterns. The primary focus of Shigematsu and colleagues'
research has been to examine the impact of SSE on fall risk factors and mobility in older
adults. Within their research they have found that SSE improves lower extremity functional
fitness, reduces fall risk, and improves overall fitness in older adults when compared to
walking or strength and balance training. In combination with Dr. Shigematsu's research in
Japan in healthy older adults, the investigators are aiming to provide a significant
evidence base for SSE internationally and within varied populations, including older adults
with subjective cognitive complaints and with different chronic diseases. In collaboration
with Dr. Shigematsu, the investigators have executed SSE studies at the Canadian Centre for
Activity and Aging and currently are running a study in the community in Woodstock, ON.
Preliminary evidence has shown that over a 6-month exercise plus mind-motor training period,
participants improved in global cognitive functioning, verbal learning and memory, and
verbal fluency, when compared to an exercise control group. Most recently, Shigematsu and
colleagues have found the SSE program to improve memory and executive function in a 6-month
pilot study.
The overarching goal of the investigators is healthy aging; research goals aim to evaluate
intervention tools in the prevention of cognitive decline at one of the earliest markers of
cognitive decline, which is a subjective complaint. As well, goals of the intervention
strategies are to maintain mobility and balance with advancing age and chronic disease. The
T2D population is at increased risk of decline and the added component of self-management of
diabetes and insulin treatment makes it crucial to maintain adequate cognition and
independence in this population.
Study Design: This study will be a 24-week Proof-of-Concept randomized controlled trial (1:1
allocation) whereby consenting and eligible participants will be randomized to either: 1)
the SSE intervention group or 2) a usual-care, wait-list control group. Participants will be
recruited from the St. Joseph's Primary Care Diabetes Support Program (SJHC- PCDSP) and the
study intervention will be conducted at a community location in London, Ontario. This will
be a single blinded study. All assessments will be done pre-intervention (V0) and
post-intervention (V2), with interim assessments after 12-weeks (V1) (with the exception of
sensorimotor). Assessments will take place at SJHC-PCDSP and Western University. One
assessment will be done online either at the participant's home or at SJHC-PCDSP (solely
completed by the participant)(i.e. Cambridge Brain Sciences). We will use blocked
randomization and thus, participants will begin and complete the trial within waves.
Participants: All participants will be required to self-report a cognitive complaint; once
eligibility is determined, participants will then be asked further questions about their
cognition. Participants will undergo a number of measurements at baseline, which will be
used to describe the study sample. These measures include: i) baseline cognition: Montreal
Cognitive Assessment (MoCA) and the Clock Drawing Test; ii) baseline fitness: Step test iii)
Anthropometric measures: weight, height, waist circumference; iv) history of physical and
mental activities: Leisure Activities questionnaire v) clinic blood work values HbA1c,
creatine (eGFR), and lipid assessment obtained from clinic electronic medical records (EMR)
and vi) demographic information. Current medications, blood pressure and patient medical
history will also be obtained from EMRs.
Intervention SSE (Intervention) Group: Participants in the Square Stepping Exercise group
will be doing a group-based mind-motor intervention program. Participants will come to a
community location for 60 minutes on one day per week to participate in the SSE program. An
instructor will be present to demonstrate the walking patterns on a gridded mat.
Participants must memorize and complete the patterns as a group, and they are encouraged to
help one another to promote social engagement. Eighty percent of the group must successfully
complete the patterns to move on to the next pattern. There are over 200 patterns that
increase in difficulty from beginner, to intermediate and advanced. If some participants are
struggling to keep up with the group, a catch-up session will be made available to assist
those participants. Participants will be asked to use the smartphone application
(Healthebrain) 10 minutes per day or 2 patterns as homework to supplement the SSE program.
Participants will be able to use their own smartphones (apple or android devices) or they
will be given a smartphone to use for the duration of the study as needed.
Wait-List Control Group: The investigators have opted to use a wait-list control group for
this study in order to see differences of our intervention from usual care in T2D.The
control group will be on a wait list to participate in the 24-week SSE program, which will
commence after all measurements are completed by both groups. The classes will be offered
free of charge.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
| Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
| Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
| Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
| Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
| Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
| Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
| Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
| Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
| Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
| Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
| Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
| Completed |
NCT02252224 -
Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance
|